SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001601485-23-000062
Filing Date
2023-10-12
Accepted
2023-10-12 07:59:08
Documents
12
Period of Report
2023-10-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K angn-20231005.htm   iXBRL 8-K 22953
  Complete submission text file 0001601485-23-000062.txt   153358

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT angn-20231005.xsd EX-101.SCH 1989
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT angn-20231005_lab.xml EX-101.LAB 25138
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT angn-20231005_pre.xml EX-101.PRE 13130
6 EXTRACTED XBRL INSTANCE DOCUMENT angn-20231005_htm.xml XML 2816
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

IRS No.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 231321728
SIC: 2834 Pharmaceutical Preparations